These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33321491)

  • 1. Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors.
    Abuzinadah AR; Alanazy MH; Butt NS; Barohn RJ; Dimachkie MM
    Eur Neurol; 2021; 84(1):43-48. PubMed ID: 33321491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.
    Bi Z; Zhan J; Zhang Q; Gao H; Yang M; Ge H; Gui M; Lin J; Bu B
    Front Immunol; 2023; 14():1177249. PubMed ID: 37266422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis.
    Chen J; Li S; Feng L; Wang H; Huang X; Feng H
    Neurol Sci; 2023 Mar; 44(3):1049-1057. PubMed ID: 36369308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
    Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
    J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.
    Abuzinadah AR; Jabari D; Jawdat O; Pasnoor M; Glenn M; Herbelin L; McVey AL; Barohn RJ; Dimachkie MM
    J Clin Neuromuscul Dis; 2018 Dec; 20(2):49-59. PubMed ID: 30439750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
    Bi Z; Ge H; Zhang Q; Gao H; Yang M; Zhan J; Lin J; Gui M; Li Y; Ji S; Cao Y; Bu B
    Pediatr Neurol; 2023 Sep; 146():31-39. PubMed ID: 37421800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
    Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
    JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
    Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of seropositive myasthenia gravis in Cape Town and South Africa.
    Bateman KJ; Schinkel M; Little F; Liebenberg L; Vincent A; Heckmann JM
    S Afr Med J; 2007 Oct; 97(10):959-62. PubMed ID: 18000579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
    Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
    J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
    Monte G; Spagni G; Damato V; Iorio R; Marino M; Evoli A
    J Neurol; 2021 May; 268(5):1803-1807. PubMed ID: 33387011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of anti-AChR-MuSK-LRP4 antibody-negative myasthenia gravis in China.
    Li W; Liu P; Cui W; Wang S; Ji Y; Zhang L; He X; Zhou S; Shen T; Zhao X; Lv J; Zhang Y; Zhang J; Fang H; Yang J; Zhang Y; Cui X; Zhang Q; Gao F
    Muscle Nerve; 2023 Jun; 67(6):481-488. PubMed ID: 36945795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
    Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
    Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis.
    Marcuse F; Brandts L; Moens D; Damoiseaux J; Hochstenbag M; Hoeijmakers JGJ; Maessen JG; De Baets M
    Eur J Neurol; 2022 Apr; 29(4):1187-1197. PubMed ID: 34967067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myasthenia gravis and pregnancy: clinical course and management of delivery and the postpartum phase].
    Ramirez C; de Seze J; Delrieu O; Stojkovic T; Delalande S; Fourrier F; Leys D; Defebvre L; Destée A; Vermersch P
    Rev Neurol (Paris); 2006 Mar; 162(3):330-8. PubMed ID: 16585888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.